The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.
The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy. The post Is Bellus Health Stock Still a Buy After 30% Earnings Jump? appeared first on The Motley Fool Canada.
Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.